Literature DB >> 28598723

Use of the Columbia-Suicide Severity Rating Scale (C-SSRS) to Classify Suicidal Behaviors.

Alejandro Interian, Megan Chesin, Anna Kline, Rachael Miller, Lauren St Hill, Miriam Latorre, Anton Shcherbakov, Arlene King, Barbara Stanley.   

Abstract

Efforts to better understand and prevent suicide have increasingly pointed to the prospective assessment of suicidal behaviors in clinical trials. These assessments are aided by instruments such as the Columbia-Suicide Severity Rating Scale (C-SSRS), which have sought to improve the conceptual uniformity and ease by which suicidal behaviors are classified. At the same time, assessment and classification of suicidal behaviors has been a longtime challenge in the field. To aid users of the C-SSRS, this article illustrates the use of the C-SSRS in instances where classification complexities arise. Illustrations are presented based on cases encountered during a clinical trial for a suicide prevention intervention. Key decision points are summarized and classification issues that warrant consideration for future refinement of such decisions are discussed.

Keywords:  assessment; classification; suicidal behavior

Mesh:

Year:  2017        PMID: 28598723     DOI: 10.1080/13811118.2017.1334610

Source DB:  PubMed          Journal:  Arch Suicide Res        ISSN: 1381-1118


  10 in total

Review 1.  Suicide in the pediatric population: screening, risk assessment and treatment.

Authors:  Mary F Cwik; Victoria M O'Keefe; Emily E Haroz
Journal:  Int Rev Psychiatry       Date:  2020-01-10

2.  The chiropractor's role in primary, secondary, and tertiary prevention of suicide: a clinical guide.

Authors:  Zachary A Cupler; Clinton J Daniels; Derek R Anderson; Michael T Anderson; Jason G Napuli; Megan E Tritt
Journal:  J Can Chiropr Assoc       Date:  2021-08

3.  Coordination of Care Between Chiropractic and Behavioral Health Practitioners Within the US Department of Veterans Affairs Health Care System: A Report of 3 Patients With Pain and Mental Health Symptoms.

Authors:  Clinton J Daniels; Derek R Anderson; Zachary A Cupler
Journal:  J Chiropr Med       Date:  2022-03-16

4.  Profile Analysis of Sexual Assault Experiences among Adult Women and Their Implications for Mental Health.

Authors:  Kihyun Kim; Bee Ryou; Jihyeon Choi; Jae-Won Kim
Journal:  Psychiatry Investig       Date:  2021-04-25       Impact factor: 2.505

5.  Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.

Authors:  Célia Fourrier; Emma Sampson; Natalie T Mills; Bernhard T Baune
Journal:  Trials       Date:  2018-08-20       Impact factor: 2.279

6.  "I thought that I had to be alive to repay my parents": Filial piety as a risk and protective factor for suicidal behavior in a qualitative study of Chinese women.

Authors:  June Sing Hong Lam; Paul S Links; Rahel Eynan; Wes Shera; A Ka Tat Tsang; Samuel Law; Wai Lun Alan Fung; Xiaoqian Zhang; Pozi Liu; Juveria Zaheer
Journal:  Transcult Psychiatry       Date:  2021-12-20

7.  Suicide Risk Management Protocol for a Randomized Controlled Trial of Cardiac Patients Reporting Hopelessness.

Authors:  Susan L Dunn; Holli A DeVon; Eileen G Collins; Anna Luong; Madison P Buursma; Melissa Gutierrez-Kapheim; Ulf G Bronas
Journal:  Nurs Res       Date:  2021 Jan/Feb       Impact factor: 2.381

8.  Suicidal ideation among Lebanese adolescents: scale validation, prevalence and correlates.

Authors:  Melissa Chahine; Pascale Salameh; Chadia Haddad; Hala Sacre; Michel Soufia; Marwan Akel; Sahar Obeid; Rabih Hallit; Souheil Hallit
Journal:  BMC Psychiatry       Date:  2020-06-15       Impact factor: 3.630

9.  A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.

Authors:  Kathy Weisel; Nicola Scott; Scott Berger; Susanne Wang; Kurt Brown; Marcy Powell; Matthijs Broer; Clarissa Watts; Debra J Tompson; Susan W Burriss; Simon Hawkins; Kathy Abbott-Banner; Paul Peter Tak
Journal:  BMJ Open Gastroenterol       Date:  2021-08

10.  Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.

Authors:  Debra J Tompson; Mark Whitaker; Rennan Pan; Geoffrey Johnson; Teresa Fuller; Litza McKenzie; Vanessa Zann; Marcy Powell; Kathy Abbott-Banner; Simon Hawkins
Journal:  Pharm Res       Date:  2021-06-16       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.